Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01231906 · ClinicalTrials.gov registry record · Phase 3
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma
A Phase 3 study, sponsored by Children's Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 642
- Enrollment target
NCT01231906 is a Phase 3 study that has completed, run by Children's Oncology Group. The registered enrollment target is 642 participants.
The verdict
NCT01231906, a Phase 3 study, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 642 participants
- Enrollment target
Study Summary
This trial examined the outcome benefit to patients of adding a new chemotherapy drug combination to the established treatment approach for patients with extracranial Ewing sarcoma, that had not spread from the primary site to other places in the body. The trial randomly assigned patients at the time of study entry to receive established standard treatment with the following 5-drugs: vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide and etoposide. The outcome for patients receiving the standard 5-drug combination was compared to the outcome for patients who received the same 5-drugs with an additional drug, topotecan hydrochloride delivered in a novel combination with vincristine sulfate and cyclophosphamide.
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin Hydrochloride
- DRUG Etoposide
- DRUG Ifosfamide
- DRUG Dexrazoxane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 642 participants |
| Start Date | 2010-11-24 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01231906
The ClinicalTrials.gov registry entry for NCT01231906 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 642 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01231906 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01231906 about?
NCT01231906 is a clinical study titled "Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma". This trial examined the outcome benefit to patients of adding a new chemotherapy drug combination to the established treatment approach for patients with extracranial Ewing sarcoma, that had not spread from the primary site to other places in the body. The trial randomly assigned patients at the tim...
What is the current status of trial NCT01231906?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 642 participants. The study started on 2010-11-24. Estimated completion is 2025-12-31.
What interventions are being tested in trial NCT01231906?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin Hydrochloride (DRUG), Etoposide (DRUG), Ifosfamide (DRUG), Dexrazoxane (DRUG).
Who is sponsoring clinical trial NCT01231906?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.